US equities |
SPCX $166.91 ▲+5.00% NVDA $236.20 ▲+0.96% MU $1,062.80 ▼-1.12% TSLA $377.13 ▲+1.77% MSFT $524.43 ▲+1.33% SNDK $1,705.31 ▼-0.85% INTC $117.12 ▼-1.85% META $742.62 ▲+2.00%
FinancialContent

Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

1.502 -0.008 (-0.55%)
Delayed Quote Updated: 12:10 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Purple Biotech Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Why Purple Biotech (PPBT) Stock Is Getting Hammered ↗
Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering. 
Via Benzinga
News headline image
Why Purple Biotech (PPBT) Shares Are Trading Lower ↗
Purple Biotech shares are trading lower by 11.5% during Monday's session. The company announced the exercise of warrants for $2 million gross proceeds. 
Via Benzinga
News headline image
Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom ↗
As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026. 
Via Stocktwits
News headline image
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Purple Biotech Stock Trading Higher On Monday? ↗
Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed improved survival rates, biomarker responses, and disease control outcomes. 
Via Benzinga
News headline image
Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024 ↗
PPBT stock results show that Purple Biotech beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
From Purple Biotech Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >